INTANGIBLE ASSETS - Nucynta Commercialization Agreement - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended	10 Months Ended	12 Months Ended	48 Months Ended
	Feb. 13, 2020	Jan. 31, 2018	Nov. 07, 2018	Dec. 31, 2018	Dec. 31, 2021	Dec. 31, 2020	Nov. 30, 2018	Nov. 08, 2018
Grnenthal | Nucynta Products
Finite-Lived Intangible Assets [Line Items]
Royalty payment as percentage of annual net sales	14.00%
Nucynta Commercialization Agreement | Assertio | Nucynta Products
Finite-Lived Intangible Assets [Line Items]
Annual minimum royalty payments		$ 537,000
2018		132,000
2019		135,000
2020		135,000
2021		135,000
Fair Value of future minimum royalty payments		$ 482,300
Discounted rate		0.057%
Interest expense			$ 19,281		$ 54,700
Amortization expense			$ 107,662
Minimum royalty paid				$ 132,000
Third Amendment to the Nucynta Commercialization Agreement | Assertio
Finite-Lived Intangible Assets [Line Items]
Number of shares that can be purchased							1,041,667
Exercise price of warrant (in dollars per share)							$ 19.20
Third Amendment to the Nucynta Commercialization Agreement | Assertio | Nucynta Products
Finite-Lived Intangible Assets [Line Items]
Number of shares that can be purchased								1,041,667
Exercise price of warrant (in dollars per share)								$ 19.20
Fair value of warrant						$ 8,043